Canterbury DHB


Chronic Myeloid Leukaemia - BCR-ABL Positive (CML)

By definition, all patients carry the BCR-ABL fusion gene, which is typically the result of the t(9;22). The fusion gene produces an abnormal tyrosine kinase, an oncoprotein which varies in size (p190, p210, p230). About 5–10% of patients do not have the typical t(9;22) or Philadelphia chromosome on karyotyping, but the BCR/ABL fusion is detectable by molecular methods (PCR or FISH). Their prognosis and response to treatment is no different from other CML patients.

In This Section

Clinical Findings

Investigation of Suspected CML




Monitoring and Response

Response Definitions, Treatment Goals and Failures

Management of Suboptimal Response, Treatment Failure, and Loss of Response

Monitoring and Management of Effects/Toxicity

Pregnancy and TKI Therapy

Treatment-free Remission – Stopping TKI Therapy

Further Reading

About this Canterbury DHB document (6211):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 6211